Stereotaxis, Inc. (STXS) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on AMEX. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Analysis Summary
Stereotaxis, Inc. reported revenue of $32.4M in the most recent fiscal year, growing at a 5-year CAGR of 4.0%.
Trailing-twelve-month margins: gross margin 55.6%, operating margin -73.0%, net margin -74.2%.
At the current price of $1.32, STXS has negative trailing earnings (P/E not meaningful) and an ROE of -132.62%. Market capitalisation stands at $129M.
Balance sheet quality for STXS: current ratio of 1.5, net cash position of $8.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.32 |
| Market Cap | $129M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 7.04 |
| EV / EBITDA | -5.77 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -132.62% |
| Return on Invested Capital | -74.49% |
| Return on Assets | -40.16% |
| Gross Margin | 55.57% |
| Operating Margin | -73.02% |
| Net Margin | -74.24% |
Financial Health
| Debt / Equity | 0.30 |
| Current Ratio | 1.42 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| STXS | Stereotaxis, Inc. | $129M | 7.04 | -132.6% | |
| 0R29.L | Intuitive Surgical, Inc. | $135.9B | 74.05 | 11.86 | 17.8% |
| ISRG | Intuitive Surgical, Inc. | $135.1B | 44.13 | 7.62 | 17.8% |
| 0R19.L | Becton, Dickinson and Company | $52.5B | 33.21 | 2.19 | 6.6% |
| BDX | Becton, Dickinson and Company | $49.0B | 54.89 | 2.05 | 3.8% |
| RMD | ResMed Inc. | $33.1B | 22.81 | 5.23 | 23.9% |
| 0KW4.L | ResMed Inc. | $31.1B | |||
| MDLN | Medline Inc. | $27.6B | 38.36 | 2.44 | 10.8% |
Price Performance
| 1 month | -2.94% |
| 3 months | -29.79% |
| Year-to-date | -42.61% |
| 1 year | -52.17% |
| 3 years | -18.01% |
52-Week Range
| 52-week High | $3.59 |
| 52-week Low | $1.24 |
| Avg Volume (90d) | 714K |
Related companies: ARCT · CVRX · HUMA · MDXH · NEO · OSUR · QTRX
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of STXS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks